New Prostate Cancer Biomarkers Can Improve Precision Therapy
Improvements are on the horizon in the treatment of prostate cancer that could improve future therapy.
Median metastasis-free survival was longer with darolutamide than with placebo: 40.4 vs 18.4 months.
In a "real world" study, biopsy and surgical grade groups 2, 3, 4, and 5 each were associated with incrementally higher risks for adverse pathologic features and biochemical recurrence.
A high percentage of men with prostate cancer have 1 or more potentially pathogenic germline variants, but would not be eligible for mutation testing under current NCCN guidelines.